Under Armour Executive Says Company’s 2020 Restructuring Plan Now Considered Closed

– Reuters Citing Conference Call

– Reuters Citing Conference Call

Total
0
Shares
Related Posts
Read More

Why Ocugen Stock Is Climbing Today

Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen said the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 has  approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.

OCGN